STAT

NOVEMBER 10, 2022

 But he was ousted in 2014 after an embarrassingly public conflict with the Sanofi board. At Sanofi, Viehbacher was largely responsible for repositioning the staid drugmaker and for deepening its partnership with Regeneron Pharmaceuticals. But Continue to STAT+ to read the full story…

Vaccines 244

Vaccines 244

Express Pharma

JANUARY 9, 2025

The data will serve as a foundation for cutting-edge research and will catalyse innovations in areas such as mRNA-based vaccines, protein manufacturing, and genetic disorder treatments. The Minister also pointed out that India is the largest vaccine producer in the world and the third-largest startup ecosystem.

Vaccines 105

Vaccines Hospitals 105

pharmaphorum

JANUARY 30, 2022

The debut was the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014, and followed a £195 million fundraising round for Oxford Nanopore in May. The Oxford University spin-out rose to prominence for commercialising the technology platform behind the Oxford/AstraZeneca COVID-19 vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

FEBRUARY 14, 2022

In a recent report by Deloitte, however, the continual decline in return on R&D investment from 2014 was reversed in a minor way in 2020, followed by a significant improvement in 2021. As a result, the internal rate of return on investment is as high in 2021 as it has been across the industry since 2014. More than meets the eye.

Vaccines 98

Vaccines 98

pharmaphorum

JULY 14, 2021

In 2014, six years after the global financial crisis forced the world’s biggest financial institutions into some serious navel gazing, the CEO of a major international bank was despairing: “We’ve put in place a best-in-class compliance system, but we can’t stop our people acting badly.

Communication 105

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

Pharmaceutical Technology

SEPTEMBER 5, 2022

Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We We want to be a sustainably growing company. billion in development.

Vaccines 114

Vaccines 114

Express Pharma

JULY 3, 2023

The Food and Drug Administration (FDA) approved an average of 43 drugs in 2014-18, compared to an average of 23 in the first decade of the century. Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle.

Biosimilars 95

Biosimilars Drug Development Generic Medicine Diabetes 95

Express Pharma

OCTOBER 9, 2024

He noted that the number of biotech startups has risen from just 50 in 2014 to over 5,000 now, reflecting India’s increasing focus on bioeconomy. He stressed the need for proactive R&D, particularly in developing countermeasures for future pandemics, and the necessity of preparedness through rapid vaccine development.

Vaccines 105

Vaccines Process Improvement Biosimilars Immunity 105

European Pharmaceutical Review

JUNE 27, 2023

About the interviewees Hervé Affagard is the CEO and co-founder of MaaT Pharma, which was established in late 2014. He has also held the role of Vice President and Therapeutic Area Head, Vaccine Clinical Research at Merck & Co. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry.

Immunity 105

Immunity Immunization Chemotherapy Vaccines 105

FDA Law Blog: Biosimilars

FEBRUARY 4, 2025

The Tropical Disease PRV program was born the very next year as part of the Food and Drug Administration Amendments Act of 2007 (FDAAA) and expanded in 2014 , which experts heralded as a game-changer for tropical disease therapies.

Vaccines 52

Vaccines 52

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 In April 2008, AstraZeneca also reached an agreement with Ranbaxy, an Indian generic drugmaker, allowing it to produce a generic version of Nexium starting in May 2014. Pfizer makes its move.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 116

European Pharmaceutical Review

JANUARY 29, 2024

Repurposing of currently marketed products, eg, methotrexate, 20 was an important and effective strategy in combatting COVID-19, particularly in the early stages prior to effective vaccines being developed. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [OBSOLETE].

Drug Development 111

Drug Development Vaccines Compounding 111

pharmaphorum

OCTOBER 1, 2021

It also won a £113 million contract to provide rapid saliva-based COVID-19 testing services to the NHS, although that was ended early by the UK government in the summer as demand fell due to vaccinations.

Documentation 52

Documentation Vaccines 52

European Pharmaceutical Review

MARCH 1, 2023

Nowhere is this more publicly evident than in the development, regulatory approval, and efficacious use of mRNA‑based vaccines for COVID-19. Beyond the high-profile COVID-19 vaccines, mRNA therapeutics are crucial in applications such as protein replacement therapies and regenerative medicine. 2014 Nov 20; 56(4), 506‑17.

Vaccines 111

Vaccines Packaging 111

RX Note

APRIL 7, 2024

Consider HPV vaccination. The incubation period can be as long as 12 months. Strategies to reduce risk of transmission include Cover warts when they are being treated. Avoid sharing towels, shoes, or socks. They tend to be rough textured and usually less than 1 cm in diameter. Surgical removal (e.g.

Compounding 52

Compounding Immunity Immunization Community Pharmacies 52

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. By 2016, Gilead already had competition for the HCV market, when MSD launched their product at €47,000 per treatment.

Vaccines 52

Vaccines 52

pharmaphorum

SEPTEMBER 9, 2021

COVID-19 also put global supply chains in the spotlight, as industry looked to remove obstacles and speed the delivery of material crucial to vaccine development processes. The aim is to work with start-up companies to generate ideas for digital therapeutics, patient support apps, and boosting research and development.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

FDA Law Blog: Biosimilars

APRIL 7, 2025

Zenrelia comes with serious warnings, including a boxed warning against the use of Zenrelia during vaccination. CVM also objected to the truncation of other information about the timing of vaccines in these promotional materials. Zenrelia promotional materials also included claims about clinical data that the Agency found actionable.

Vaccines 64

Vaccines Adverse Reactions 64

PharmaShots

FEBRUARY 21, 2023

Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells.

Dosage 56

Dosage Labelling Immunity Immunization 56

STAT

JANUARY 11, 2023

When I learned that an outbreak of Ebola was declared in Uganda last fall, I had a flashback to 2014 when I was working at Merck and an outbreak of Ebola disease caused by a different species of the virus emerged in full force in West Africa.

Vaccines 246

Vaccines 246

PharmaShots

MAY 23, 2023

Stock Exchange: TYO With focus areas extending to the discovery and development of biopharma products, AnGes is dedicated to developing genetic medicines and therapeutic vaccines for intractable or rare diseases. Approved Cell and Gene Therapy: Collategene Founded Year: 1999 Total Employees: ~140 Headquarters: Osaka, Japan Market Cap: $162.8M

Diabetes 58

Diabetes Immunity Immunization Pharmaceutical Companies 58

FDA Law Blog: Biosimilars

JANUARY 7, 2024

To better understand FDA’s approach in classifying postmarketing pregnancy studies as PMRs or PMCs, we reviewed all postmarketing requirements (PMRs) and postmarketing commitments (PMCs) related to maternal and fetal outcomes in FDA’s PMR/PMC database for drugs approved in the ten-year period from January 2014 through December 2023.

Documentation 59

Documentation Vaccines Drug Development 59

pharmaphorum

MAY 20, 2022

She began her career in clinical research as a clinical trial assistant for Novartis Vaccines and Diagnostics in 2007 and continued to pursue her interest is vaccine research in 2014 when she joined GSK (formerly Novartis Vaccines). Sheena has a wealth of experience of managing and delivering clinical trials.

Hospitals 59

Hospitals Medical Records Vaccines Diabetes 59

pharmaphorum

MARCH 1, 2022

This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. She began her career in clinical research as a clinical trial assistant for Novartis Vaccines and Diagnostics in 2007 and continued to pursue her interest is vaccine research in 2014 when she joined GSK (formerly Novartis Vaccines).

Vaccines 96

Vaccines Hospitals 96

pharmaphorum

NOVEMBER 16, 2020

In his final message as head of the EMA, Rasi said the number of COVID-19 drugs and vaccines being developed by pharma companies is “encouraging,” and pointing to the agency’s pivotal role “in reviewing the available data packages to ensure that our usual high standards of safety, efficacy and quality are achieved and upheld.”.

Vaccines 64

Vaccines Packaging 64

Quality Matters

JUNE 13, 2023

Many regulatory authorities moved quickly to use emergency authority to approve new therapeutic treatments and vaccines for COVID-19. FDA issued the first emergency use authorization for a COVID-19 vaccine on Dec. For example, the U.S. 11, 2020, less than a year after WHO declared the coronavirus a global pandemic in March 2020.

Communication 52

Communication Vaccines 52

Quality Matters

JUNE 21, 2023

While WHO began assessing regulatory systems in 1997, work on the unified tool began in 2014 and it has subsequently incorporated various revisions in response to stakeholder feedback. Collecting real world safety data, including country-specific data, and information sharing was key to ensuring safety of COVID vaccines.”

Vaccines 52

Vaccines 52

pharmaphorum

APRIL 19, 2021

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham.

Vaccines 98

Vaccines 98

PharmaShots

APRIL 13, 2023

and became a leader in the medical device industry Novartis raised its sales by 16% and acquired Alcon (ophthalmic business), Genoptix (oncology business), and an 85% stake in Zhejiang Tianyuan (vaccine business) Bayer recorded a revenue of $49B as its pharmaceutical business posted an encouraging performance in the emerging market.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

PharmExec

MARCH 13, 2024

Data shows that from 2014-2019, pneumococcal vaccinations in seniors increased by 10%, growing sales for Prevnar 13 due to government recommendation in addition to a high-profile advertising campaign.

Vaccines 52

Vaccines 52

PharmaShots

JANUARY 31, 2023

The Company's premier line of smart safety syringes, Sharps Provensa, prevents accidental needlestick injuries, prevents needle reuse, and minimizes drug and vaccine waste—all while maintaining the intuitive simplicity of conventional syringes. Founded Year: 2014 No. Funding Value: $15.9M Founded Year: 2007 No. of Shares: 3.7M

Vaccines 40

Vaccines Immunity Immunization Diabetes 40

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunity Immunization 111

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MAY 25, 2021

She went on to describe another study, EAVE II , which has drawn on BREATHE’s expertise, linking patient data across the entire Scottish population to provide the first real-world evidence of the success of the COVID-19 vaccination programme in cutting risk of hospital admission. About Savana.

Hospitals 104

Hospitals Vaccines 104

pharmaphorum

JUNE 10, 2021

The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are the keys to ending disease, curing chronic conditions, and discovering new therapies and vaccines that address the latest medical challenges.

Drug Pricing 105

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

pharmaphorum

DECEMBER 2, 2020

In 2014 the company made an offer of around $100 billion to acquire UK firm AstraZeneca (which at the time was going through a rough patch ). The $12 billion deal was cleared in November 2020, creating a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word.

Compounding 128

Compounding Vaccines Biosimilars Diabetes 128

pharmaphorum

SEPTEMBER 21, 2020

AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s busy pipeline is producing successes in other areas. Lynparza was the first PARP (poly (ADP-ribose) polymerase) drug on the market in 2014, first approved in the US for ovarian cancer. months versus 17.7

Labelling 52

Labelling Vaccines 52